Cashing Out: When the Government's Watchdogs Go to Work for the Wolves

In the spring of 2019, a senior EPA official who had spent the better part of a decade overseeing pesticide safety reviews quietly submitted his resignation. Within eight months, he had accepted a senior advisory role at one of the country's largest agrochemical manufacturers — a company whose flagship herbicide he had helped shepherd through a contested re-registration process just the year before. His salary, according to financial disclosures reviewed by DOE News, more than tripled.

His story is not unusual. It is, by most measures, routine.

Across the federal regulatory apparatus — from the Food and Drug Administration to the Federal Communications Commission to the Securities and Exchange Commission — a well-worn career path has emerged over the past three decades. Officials accumulate institutional knowledge, regulatory access, and personal relationships at public expense, then monetize those assets in the private sector. The practice is known colloquially as the revolving door, and while it has been studied, criticized, and occasionally legislated against, it continues to operate with remarkable efficiency.

The Numbers Behind the Pattern

A 2023 analysis by the Government Accountability Project found that more than 60 percent of senior officials who departed the FDA between 2016 and 2022 subsequently took positions in pharmaceutical, biotech, or medical device companies. At the FCC, a separate review by the watchdog group Public Citizen identified at least 34 former commissioners and senior staff members who moved into telecom industry roles during the same period — many of them within the legally mandated one-year cooling-off window's immediate aftermath.

The financial incentives are not subtle. A mid-level division director at a federal agency might earn between $130,000 and $175,000 annually. The same individual, repackaged as a regulatory affairs consultant or senior lobbyist for a Fortune 500 firm, can command two to four times that figure. In specialized fields such as pharmaceutical approval pathways or spectrum licensing, the premium is higher still.

"What you're really selling is the Rolodex and the institutional memory," said one former FDA reviewer who asked not to be identified by name, citing ongoing consulting work. "You know which reviewers are skeptical of what kinds of data. You know how to frame a submission. That's worth a great deal to a company trying to get a drug approved."

Legal Loopholes and Cooling-Off Illusions

Federal law does impose some restrictions on post-government employment. Under 18 U.S.C. § 207, senior officials are prohibited from lobbying their former agencies on specific matters in which they were personally and substantially involved, typically for a period of one to two years depending on their rank. Cabinet secretaries and certain other senior officials face a broader two-year ban.

But the law contains significant gaps that practitioners have long learned to exploit. The restrictions apply to direct lobbying — formal, registered contacts with agency personnel — not to the broader category of strategic consulting, where former officials advise companies on regulatory positioning without technically appearing as registered lobbyists. This distinction, critics argue, renders the cooling-off period largely cosmetic.

"The one-year ban sounds meaningful until you realize it only covers a very narrow slice of what these people actually do for their new employers," said Dr. Kathleen Marchetti, a government ethics researcher at American University. "They can sit in on strategy sessions, review draft submissions, coach junior lobbyists on how to approach former colleagues. None of that is captured by the statute."

The Office of Government Ethics, the agency nominally responsible for enforcing these standards, operates with a staff of fewer than 80 employees and has no independent investigative authority. Enforcement actions are rare; criminal prosecutions are rarer still.

Policy Reversals and Convenient Timing

Perhaps more troubling than the career transitions themselves is the question of whether regulatory decisions are shaped in anticipation of them. DOE News reviewed a series of agency rulings issued in the final twelve to eighteen months of officials' tenures and compared them against subsequent employment disclosures.

In several documented instances, the alignment is striking. One FCC official who voted in 2017 to weaken broadband privacy rules — rules that primarily benefited large internet service providers — joined a major ISP's government affairs team fourteen months later. An EPA administrator who oversaw the rollback of methane emission standards for oil and gas operations subsequently accepted a position with an energy industry trade association.

None of these transitions are, on their face, illegal. And correlation is not causation. But the pattern, when viewed in aggregate, raises questions that existing ethics frameworks are not designed to answer.

"The problem isn't always that someone makes a corrupt deal," said Craig Holman, a government affairs lobbyist for Public Citizen who has tracked revolving door legislation for two decades. "The problem is that the entire incentive structure is oriented toward pleasing future employers. You don't need an explicit quid pro quo when the implicit one is baked into the career trajectory."

The Cost to the Public Interest

Quantifying what the revolving door costs taxpayers is methodologically difficult, but researchers have attempted to do so in specific sectors. A 2021 study published in the Journal of Health Politics, Policy and Law estimated that regulatory delays attributable to pharmaceutical industry influence — influence that flowed in part through former FDA officials — contributed to extended periods of brand-name drug exclusivity that cost Medicare and Medicaid programs billions of dollars in foregone generic savings.

In the telecommunications sector, critics have argued that the FCC's reluctance to impose robust net neutrality rules — a position held through multiple administrations and shaped in part by officials who later joined telecom companies — allowed industry consolidation that reduced competition and sustained artificially high consumer prices.

These are contested claims, and industry representatives push back vigorously. Trade associations argue that former regulators bring valuable technical expertise to the private sector and that their presence actually improves compliance. The pharmaceutical industry, in particular, contends that experienced FDA alumni help companies navigate complex approval processes more efficiently, ultimately speeding beneficial treatments to market.

Reform Efforts: Ambitious on Paper, Limited in Practice

Legislative attempts to address the revolving door have accumulated over the years without producing structural change. The ETHICS Act, introduced in various forms since 2019, would extend cooling-off periods to five years for certain senior officials and expand the definition of prohibited post-government activities. It has not advanced past committee in any Congress.

President Biden issued an executive order in January 2021 requiring political appointees to sign ethics pledges extending their lobbying bans, but executive orders can be revoked by subsequent administrations, and they do not bind career officials, who constitute the majority of those cycling between government and industry.

State-level experiments offer some instructive data points. California and New York have implemented stricter revolving door restrictions for certain state agency officials, and early assessments suggest modest reductions in immediate post-government industry employment. Whether those findings translate to the federal context remains an open question.

What is not an open question is that the current system, as designed, permits — and in many respects rewards — the commodification of public service. Until Congress either closes the statutory loopholes or creates a genuinely independent enforcement mechanism with investigative authority, the revolving door will continue to spin, and the public interest will continue to pay the entry fee.